Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopathology and clinical features
Approximately 30-50% of cases of ovarian adenocarcinoma harbour mutations in the p53 tumour-suppressor gene associated with elevated levels of the protein detected by immunohistochemical staining. To investigate any relation between the presence of mutant p53 and clinicopathological features of dise...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 1994-03, Vol.69 (3), p.609-612 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 612 |
|---|---|
| container_issue | 3 |
| container_start_page | 609 |
| container_title | British journal of cancer |
| container_volume | 69 |
| creator | RENNINSON, J BAKER, B. W MCGOWN, A. T MURPHY, D NORTON, J. D FOX, B. W CROWTHER, D |
| description | Approximately 30-50% of cases of ovarian adenocarcinoma harbour mutations in the p53 tumour-suppressor gene associated with elevated levels of the protein detected by immunohistochemical staining. To investigate any relation between the presence of mutant p53 and clinicopathological features of disease, we examined a series of 50 cases of epithelial ovarian adenocarcinoma for expression of p53 by immunohistological staining on fixed, paraffin-embedded tissue sections using the polyclonal antibody CM1, and by direct nucleotide sequencing of polymerase chain reaction-amplified DNA from selected cases. Of the 50 cases examined, 28 (56%) were p53 positive and there was no significant correlation between p53 status and differentiation stage, clinical (FIGO) stage, multidrug resistance (mdr-1 P-glycoprotein) expression or response to treatment. However, we observed a statistically significant difference between the high prevalence of p53-positive serous tumours (18 out of 23) and the lower prevalence of p53-positive cases in mucinous tumours (3 of 12) suggesting that factors related to disease aetiology, associated with these histological subtypes, may determine the prevalence of functional inactivation of the p53 tumour-suppressor gene in ovarian adenocarcinoma. |
| doi_str_mv | 10.1038/bjc.1994.113 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1968836</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76384874</sourcerecordid><originalsourceid>FETCH-LOGICAL-c464t-817877533794345d8859424aa49b662842133e3c326a5cf8f4eef3eff76383b73</originalsourceid><addsrcrecordid>eNqFkU2vEyEYhYnRXGt159aEhXHl1GFgBnBxE9P40eQaN7omlL7TcsPACMw1_UH-T5m2aXRlQkLIeTiHl4PQS1KvSE3Fu-29WREp2YoQ-ggtSEubioiGP0aLuq55VcumfoqepXRfjrIW_AbdCNJQJsUC_d4Mw-TDwaYczAEGa7TDO8hgsg0ehx4PU9Y-47GleIwhg_W4LBhtPoCzhQ4POlrtsdHeQMRTsn6Px-COxgVf9HLbbsPuiNdfN--xCTGC0yf3X8UDn6JHnQ_Bhf2x0DtsnPWnh_Sg8xQhPUdPeu0SvLjsS_Tj08fv6y_V3bfPm_WHu8qwjuVKEC44bynlklHW7oRoJWuY1kxuu64RrCGUAjW06XRretEzgJ5C3_OOCrrldIluz77jtB1gZ8DnqJ0aox10PKqgrfpX8fag9uFBEdkJQbti8OZiEMPPCVJWg00GnNMewpTUHMQEZ_8FSScI68ooS_T2DJoYUorQX19DajX3r0r_au5flf4L_urvCa7wpfCiv77oOpUf7mMpzaYrRiWXUs5z4DPmTwVc9ZI1R81JfwB3jsfd</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16814653</pqid></control><display><type>article</type><title>Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopathology and clinical features</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Nature Journals Online</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>RENNINSON, J ; BAKER, B. W ; MCGOWN, A. T ; MURPHY, D ; NORTON, J. D ; FOX, B. W ; CROWTHER, D</creator><creatorcontrib>RENNINSON, J ; BAKER, B. W ; MCGOWN, A. T ; MURPHY, D ; NORTON, J. D ; FOX, B. W ; CROWTHER, D</creatorcontrib><description>Approximately 30-50% of cases of ovarian adenocarcinoma harbour mutations in the p53 tumour-suppressor gene associated with elevated levels of the protein detected by immunohistochemical staining. To investigate any relation between the presence of mutant p53 and clinicopathological features of disease, we examined a series of 50 cases of epithelial ovarian adenocarcinoma for expression of p53 by immunohistological staining on fixed, paraffin-embedded tissue sections using the polyclonal antibody CM1, and by direct nucleotide sequencing of polymerase chain reaction-amplified DNA from selected cases. Of the 50 cases examined, 28 (56%) were p53 positive and there was no significant correlation between p53 status and differentiation stage, clinical (FIGO) stage, multidrug resistance (mdr-1 P-glycoprotein) expression or response to treatment. However, we observed a statistically significant difference between the high prevalence of p53-positive serous tumours (18 out of 23) and the lower prevalence of p53-positive cases in mucinous tumours (3 of 12) suggesting that factors related to disease aetiology, associated with these histological subtypes, may determine the prevalence of functional inactivation of the p53 tumour-suppressor gene in ovarian adenocarcinoma.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.1994.113</identifier><identifier>PMID: 8123498</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>Basingstoke: Nature Publishing Group</publisher><subject>Base Sequence ; Biological and medical sciences ; Codon ; DNA Primers ; DNA, Neoplasm - analysis ; Exons ; Female ; Female genital diseases ; Genes, p53 ; Gynecology. Andrology. Obstetrics ; Humans ; Immunohistochemistry - methods ; Medical sciences ; Molecular Sequence Data ; Neoplasm Staging ; Ovarian Neoplasms - genetics ; Ovarian Neoplasms - pathology ; Point Mutation ; Polymerase Chain Reaction ; Tumor Suppressor Protein p53 - analysis ; Tumor Suppressor Protein p53 - genetics ; Tumors</subject><ispartof>British journal of cancer, 1994-03, Vol.69 (3), p.609-612</ispartof><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c464t-817877533794345d8859424aa49b662842133e3c326a5cf8f4eef3eff76383b73</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968836/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968836/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,2725,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=3979996$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8123498$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>RENNINSON, J</creatorcontrib><creatorcontrib>BAKER, B. W</creatorcontrib><creatorcontrib>MCGOWN, A. T</creatorcontrib><creatorcontrib>MURPHY, D</creatorcontrib><creatorcontrib>NORTON, J. D</creatorcontrib><creatorcontrib>FOX, B. W</creatorcontrib><creatorcontrib>CROWTHER, D</creatorcontrib><title>Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopathology and clinical features</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><description>Approximately 30-50% of cases of ovarian adenocarcinoma harbour mutations in the p53 tumour-suppressor gene associated with elevated levels of the protein detected by immunohistochemical staining. To investigate any relation between the presence of mutant p53 and clinicopathological features of disease, we examined a series of 50 cases of epithelial ovarian adenocarcinoma for expression of p53 by immunohistological staining on fixed, paraffin-embedded tissue sections using the polyclonal antibody CM1, and by direct nucleotide sequencing of polymerase chain reaction-amplified DNA from selected cases. Of the 50 cases examined, 28 (56%) were p53 positive and there was no significant correlation between p53 status and differentiation stage, clinical (FIGO) stage, multidrug resistance (mdr-1 P-glycoprotein) expression or response to treatment. However, we observed a statistically significant difference between the high prevalence of p53-positive serous tumours (18 out of 23) and the lower prevalence of p53-positive cases in mucinous tumours (3 of 12) suggesting that factors related to disease aetiology, associated with these histological subtypes, may determine the prevalence of functional inactivation of the p53 tumour-suppressor gene in ovarian adenocarcinoma.</description><subject>Base Sequence</subject><subject>Biological and medical sciences</subject><subject>Codon</subject><subject>DNA Primers</subject><subject>DNA, Neoplasm - analysis</subject><subject>Exons</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Genes, p53</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Immunohistochemistry - methods</subject><subject>Medical sciences</subject><subject>Molecular Sequence Data</subject><subject>Neoplasm Staging</subject><subject>Ovarian Neoplasms - genetics</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Point Mutation</subject><subject>Polymerase Chain Reaction</subject><subject>Tumor Suppressor Protein p53 - analysis</subject><subject>Tumor Suppressor Protein p53 - genetics</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU2vEyEYhYnRXGt159aEhXHl1GFgBnBxE9P40eQaN7omlL7TcsPACMw1_UH-T5m2aXRlQkLIeTiHl4PQS1KvSE3Fu-29WREp2YoQ-ggtSEubioiGP0aLuq55VcumfoqepXRfjrIW_AbdCNJQJsUC_d4Mw-TDwaYczAEGa7TDO8hgsg0ehx4PU9Y-47GleIwhg_W4LBhtPoCzhQ4POlrtsdHeQMRTsn6Px-COxgVf9HLbbsPuiNdfN--xCTGC0yf3X8UDn6JHnQ_Bhf2x0DtsnPWnh_Sg8xQhPUdPeu0SvLjsS_Tj08fv6y_V3bfPm_WHu8qwjuVKEC44bynlklHW7oRoJWuY1kxuu64RrCGUAjW06XRretEzgJ5C3_OOCrrldIluz77jtB1gZ8DnqJ0aox10PKqgrfpX8fag9uFBEdkJQbti8OZiEMPPCVJWg00GnNMewpTUHMQEZ_8FSScI68ooS_T2DJoYUorQX19DajX3r0r_au5flf4L_urvCa7wpfCiv77oOpUf7mMpzaYrRiWXUs5z4DPmTwVc9ZI1R81JfwB3jsfd</recordid><startdate>19940301</startdate><enddate>19940301</enddate><creator>RENNINSON, J</creator><creator>BAKER, B. W</creator><creator>MCGOWN, A. T</creator><creator>MURPHY, D</creator><creator>NORTON, J. D</creator><creator>FOX, B. W</creator><creator>CROWTHER, D</creator><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19940301</creationdate><title>Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopathology and clinical features</title><author>RENNINSON, J ; BAKER, B. W ; MCGOWN, A. T ; MURPHY, D ; NORTON, J. D ; FOX, B. W ; CROWTHER, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c464t-817877533794345d8859424aa49b662842133e3c326a5cf8f4eef3eff76383b73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Base Sequence</topic><topic>Biological and medical sciences</topic><topic>Codon</topic><topic>DNA Primers</topic><topic>DNA, Neoplasm - analysis</topic><topic>Exons</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Genes, p53</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Immunohistochemistry - methods</topic><topic>Medical sciences</topic><topic>Molecular Sequence Data</topic><topic>Neoplasm Staging</topic><topic>Ovarian Neoplasms - genetics</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Point Mutation</topic><topic>Polymerase Chain Reaction</topic><topic>Tumor Suppressor Protein p53 - analysis</topic><topic>Tumor Suppressor Protein p53 - genetics</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>RENNINSON, J</creatorcontrib><creatorcontrib>BAKER, B. W</creatorcontrib><creatorcontrib>MCGOWN, A. T</creatorcontrib><creatorcontrib>MURPHY, D</creatorcontrib><creatorcontrib>NORTON, J. D</creatorcontrib><creatorcontrib>FOX, B. W</creatorcontrib><creatorcontrib>CROWTHER, D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>RENNINSON, J</au><au>BAKER, B. W</au><au>MCGOWN, A. T</au><au>MURPHY, D</au><au>NORTON, J. D</au><au>FOX, B. W</au><au>CROWTHER, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopathology and clinical features</atitle><jtitle>British journal of cancer</jtitle><addtitle>Br J Cancer</addtitle><date>1994-03-01</date><risdate>1994</risdate><volume>69</volume><issue>3</issue><spage>609</spage><epage>612</epage><pages>609-612</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Approximately 30-50% of cases of ovarian adenocarcinoma harbour mutations in the p53 tumour-suppressor gene associated with elevated levels of the protein detected by immunohistochemical staining. To investigate any relation between the presence of mutant p53 and clinicopathological features of disease, we examined a series of 50 cases of epithelial ovarian adenocarcinoma for expression of p53 by immunohistological staining on fixed, paraffin-embedded tissue sections using the polyclonal antibody CM1, and by direct nucleotide sequencing of polymerase chain reaction-amplified DNA from selected cases. Of the 50 cases examined, 28 (56%) were p53 positive and there was no significant correlation between p53 status and differentiation stage, clinical (FIGO) stage, multidrug resistance (mdr-1 P-glycoprotein) expression or response to treatment. However, we observed a statistically significant difference between the high prevalence of p53-positive serous tumours (18 out of 23) and the lower prevalence of p53-positive cases in mucinous tumours (3 of 12) suggesting that factors related to disease aetiology, associated with these histological subtypes, may determine the prevalence of functional inactivation of the p53 tumour-suppressor gene in ovarian adenocarcinoma.</abstract><cop>Basingstoke</cop><pub>Nature Publishing Group</pub><pmid>8123498</pmid><doi>10.1038/bjc.1994.113</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 1994-03, Vol.69 (3), p.609-612 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1968836 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Nature Journals Online; PubMed Central; SpringerLink Journals - AutoHoldings |
| subjects | Base Sequence Biological and medical sciences Codon DNA Primers DNA, Neoplasm - analysis Exons Female Female genital diseases Genes, p53 Gynecology. Andrology. Obstetrics Humans Immunohistochemistry - methods Medical sciences Molecular Sequence Data Neoplasm Staging Ovarian Neoplasms - genetics Ovarian Neoplasms - pathology Point Mutation Polymerase Chain Reaction Tumor Suppressor Protein p53 - analysis Tumor Suppressor Protein p53 - genetics Tumors |
| title | Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopathology and clinical features |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T05%3A19%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunohistochemical%20detection%20of%20mutant%20p53%20protein%20in%20epithelial%20ovarian%20cancer%20using%20polyclonal%20antibody%20CMI:%20correlation%20with%20histopathology%20and%20clinical%20features&rft.jtitle=British%20journal%20of%20cancer&rft.au=RENNINSON,%20J&rft.date=1994-03-01&rft.volume=69&rft.issue=3&rft.spage=609&rft.epage=612&rft.pages=609-612&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.1994.113&rft_dat=%3Cproquest_pubme%3E76384874%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16814653&rft_id=info:pmid/8123498&rfr_iscdi=true |